期刊
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
卷 27, 期 2, 页码 E186-E190出版社
WILEY
DOI: 10.1111/j.1468-3083.2012.04571.x
关键词
-
类别
资金
- Human Physiopathology Programm of the Fondation pour la Recherche Medicale (FRM)
Background Psoriasis is frequently associated with overweight and obesity. Anti-TNF-alpha therapies are effective in the treatment of psoriasis. TNF-alpha is highly involved in body weight regulation. Objective Our objective was to evaluate the increase in weight throughout the treatment with infliximab and the association of weight gain with the body mass index (BMI). Methods Thirty-five patients affected with severe plaque psoriasis receiving infliximab were included. A control group consisted of 16 patients affected with severe plaque psoriasis and treated with cyclosporine, methotrexate, or acitretin. Assessment of PASI score, body weight and BMI were performed at a 1 and 3-year follow-up. Results We observed a body weight increment of 2.5 +/- 4.4 kg (mean +/- SD) (i.e. + 3.6% of baseline) and 0.1 +/- 5 kg (i.e. + 1.2%) in patients treated with infliximab and the control group, respectively (P = 0.046), after 1 year of treatment. After 3 years of infliximab administration, weight gain was 4.8 +/- 5 kg (n = 16) (i.e. + 6%) (P = 0.005). Moreover, as classified by BMI, normal weight patients experienced a 4 +/- 3.7 kg weight gain (i.e. + 6%) whereas overweight and obese patients had gained 1.3 +/- 4.8 kg (i.e. + 1.2%) (P = 0.039) after 1 year of anti-TNF-alpha therapy. Percentual changes in body weight were larger in normal weight patients at baseline than in overweight/obese counterparts (P = 0.0149). Conclusion All patients, including normal weight patients, should receive a dietary intervention. Received: 20 January 2012; Accepted: 10 April 2012.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据